Literature DB >> 20655695

[How can we diagnose and better understand inflammatory myopathies? The usefulness of auto-antibodies].

Jean Sibilia1, Emmanuel Chatelus, Alain Meyer, Jacques-Eric Gottenberg, Christelle Sordet, Joëlle Goetz.   

Abstract

The inflammatory myopathies are a group of quite proteiform, systemic auto-immune diseases which include polymyositis, dermatomyositis and inclusion body myopathies. To facilitate the diagnosis, classification criteria (Bohan and Peter, 1975) have been proposed, based essentially on clinical criteria. In addition, over the past fifteen years, auto-antibodies characterizing certain forms of inflammatory myopathy have been identified. One distinguishes schematically: auto-antibodies specific for myositis and auto-antibodies sometimes associated with myositis. Concerning the myositis specific auto-antibodies (MSA), schematically there are a dozen specificities which are classed according to the cellular distribution of the auto-antigen. The most characteristic are certainly the auto-antibodies directed against cytoplasmic antigens: the anti-tRNA synthetases (anti-Jo-1 (PL-1), anti-PL-7, PL-12, EJ, OJ, JS, KS, ZO, YRS), anti-SRP (signal recognition particle), anti-Mas and anti-KJ, anti-Fer (eEF1), anti-Wa and anti-CADM p140. Other auto-antibodies are directed against nuclear auto-antigens: the anti-Mi-2, anti-PMS (PMS1, PMS2) and related antibodies (MLH1, DNA PKcs…), anti-56 kDa, anti-MJ (NXP-2), anti-SAE and anti-p155/p140 (TIF-1γ). Concerning the auto-antibodies sometimes associated with myositis (myositis associated auto-antibodies or MAA), they can also be observed in other auto-immune diseases. These auto-antibodies are directed against nuclear or nucleolar auto-antigens: the anti-PM-Scl, anti-Ku, anti-RNP (U1 RNP and U2 RNP, U4/U6 RNP and U5 RNP), anti-Ro 52 kDa and more rarely, anti-Ro 60 kDa and anti-La. The auto-antibodies related to myositis are biological tools which are of interest in two main ways. They have allowed us to sort out the nosology of these inflammatory myopathies, in particular by defining anti-tRNA synthetase syndrome. It now remains to determine how they might be employed to complement the classical clinico-biological diagnostic criteria. In this perspective, it will be indispensable first of all to diffuse and standardize the methods of detection. The latter are at the moment very heterogeneous as they use techniques and above all antigenic preparations which are extremely diverse. These antibodies are also very interesting "physiopathological" tools to try to better understand myositis. The example of anti-tRNA synthetases is a particularly original model of auto-immunization, which allows one to establish a link between an initial, probably poorly specific muscular lesion and the appearance of auto-antibodies which maintain and aggravate the muscular disease.
Copyright © 2010 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20655695     DOI: 10.1016/j.lpm.2010.06.008

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  5 in total

Review 1.  The impact of anti-U1-RNP positivity: systemic lupus erythematosus versus mixed connective tissue disease.

Authors:  Alina Dima; Ciprian Jurcut; Cristian Baicus
Journal:  Rheumatol Int       Date:  2018-05-23       Impact factor: 2.631

2.  Camptocormia as a clinical manifestation of polymyositis/systemic sclerosis overlap myositis associated with anti-Ku.

Authors:  Thierry Zenone; Nathalie Streichenberger; Marie Puget
Journal:  Rheumatol Int       Date:  2012-03-28       Impact factor: 2.631

Review 3.  Exosomes as a Nanodelivery System: a Key to the Future of Neuromedicine?

Authors:  Arian Aryani; Bernd Denecke
Journal:  Mol Neurobiol       Date:  2014-12-15       Impact factor: 5.590

4.  Anti-ro52 antibodies and interstitial lung disease in connective tissue diseases excluding scleroderma.

Authors:  João Pedro Ferreira; Isabel Almeida; António Marinho; Conceição Cerveira; Carlos Vasconcelos
Journal:  ISRN Rheumatol       Date:  2012-03-27

Review 5.  Bench to bedside review of myositis autoantibodies.

Authors:  Boaz Palterer; Gianfranco Vitiello; Alessia Carraresi; Maria Grazia Giudizi; Daniele Cammelli; Paola Parronchi
Journal:  Clin Mol Allergy       Date:  2018-03-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.